Conflict of interest statement: CONFLICTS OF INTEREST Michael Weller has 
received research grants from Acceleron, Bayer, Isarna, MSD, Merck Serono, PIQUR 
and Roche and honoraria for lectures or advisory board participation from 
Celldex, Isarna, Magforce, MSD, Merck Serono, Pfizer, Roche and Teva. Louis Burt 
Nabors serves in an uncompensated advisory board role for Merck Serono. Thierry 
Gorlia reports no disclosures. Henning Leske reports no disclosures. Elisabeth 
Rushing reports no disclosures. Pierre Bady reports no disclosures. Christine 
Hicking is an employee and stockowner of Merck KGaA. James Perry has received 
honoraria for lectures or advisory board participation from Merck, MSD, 
Midatech, and Roche. Yong-Kil Hong reports no disclosures. Patrick Roth has 
received honoraria for advisory boards or lectures from Roche, MSD, Novartis and 
Molecular Partners. Wolfgang Wick has received research grants from Apogenix, 
Boehringer Ingelheim, Eli Lilly, immatics, MSD and Roche as well as honoraria 
for lectures or advisory board participation from MSD and Roche. Simon Goodman 
is a Merck KGaA employee and holds patents on the integrin antibodies used in 
this study. Monika Hegi has received an honorary for advisory board 
participation from MSD, Merck Serono, Roche, and MDxHealth. Martin Picard is a 
Merck KGaA employee. Holger Moch has received research grants from Merck Serono. 
Josef Straub is a Merck KGaA employee. Roger Stupp has served on advisory boards 
for Roche/Genentech, MSD and EMD-Serono/Merck.